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Abstract
Background: Increasing clinical data supports a low a/b ratio for prostate adenocarcinoma, potentially lower than
that of surrounding normal tissues. A hypofractionated, weekly radiation therapy (RT) schedule should result in
improved tumour control, reduced acute toxicity, and similar or decreased late effects. We report the toxicity
profile of such treatment.
Materials and Methods: We conducted a multi-institution phase I/II trial of three-dimensional conformal radiation
therapy (3D-CRT) for favourable-risk prostate cancer (T1a-T2a, Gleason ≤ 6 and PSA < 10 ng/ml). RT consisted of 45
Gy in nine 5 Gy fractions, once weekly. Primary end-points were feasibility and late gastrointestinal (GI) toxicity
(RTOG scale), while secondary end-points included acute GI toxicity, acute and late genitourinary (GU) toxicity,
biochemical control, and survival.
Results: Between 2006 and 2008, 80 patients were treated. No treatment interruptions occurred. The median
follow-up is 33 months (range: 20-51). Maximal grade 1, 2, and 3 acute (< 3 months) GU toxicity was 29%, 31%
and 5% respectively (no grade 4). Acute GI grade 1 toxicity was reported in 30% while grade 2 occurred in 14%
(no grade 3 or 4). Crude late grade ≥ 3 toxicity rates at 31 months were 2% for both GU and GI toxicity.
Cumulative late grade ≥ 3 GI toxicity at 3 years was 11%. Two patients had PSA failure according to the Phoenix
definition. The three-year actuarial biochemical control rate is 97%.
Conclusions: Weekly RT with 45 Gy in 9 fractions is feasible and results in comparable toxicity. Long term tumour
control and survival remain to be assessed.
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Background
In recent years, there has been increasing interest in
hypofractionated radiation therapy (RT) for prostate
cancer. Using the linear-quadratic (LQ) model for the
effect of RT on tumour, emerging data supports a low
alpha/beta (a/b) ratio for prostatic adenocarcinoma
cells. Values of a/b ranging from 1.2 to 4 have been
reported [1-8], with most data supporting values at the
lower end of this spectrum. Furthermore, the a/b ratio
for late rectal effects may be higher (around 4-6) [5]
than the value of 3 for other late tissue effects. In this
case, the LQ model predicts that a hypofractionated
regimen would result in superior tumour control with a
similar rate of late toxicity or lower late toxicity with a
similar tumour control rate. Thus, a favourable thera-
peutic ratio can potentially be achieved by delivering a
small number of larger fractions. However, hypofractio-
nation can lead to more severe acute effects and
increased consequential late damage. This can be pre-
vented by increasing the time between fractions, which
allows for normal tissue recovery without compromising
efficacy when the tumour a/b is low.
In addition to the possible radiobiological benefits,
hypofractionated RT with fewer fractions allows for
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to their lives. Other potential benefits are reduction in
treatment costs for centralized health care systems and
shortening of waiting lists in high volume treatment
centers.
In 2006, we opened a phase I-II prospective trial of
hypofractionated 3D-CRT for favourable-risk prostate
cancer patients. The regimen consisted of 45 Gy in 5 Gy
fractions, given once a week over nine weeks (57 days).
Using the LQ model without time correction, this corre-
sponds to a biologically equivalent dose (BED) of 83.6
Gy in 2 Gy fractions (EQD2) assuming an a/b ratio of
1 . 5 .T h eB E Df o rl a t ee f f e c t so nn o r m a lt i s s u ei s7 2G y
in 2 Gy fractions assuming an a/b ratio of 3.
Our findings of acute toxicity and preliminary late
toxicity results are reported here, along with a compari-
son with other clinical hypofractionated studies in pros-
tate cancer.
Methods
Study Population
Eligible men had histologically confirmed prostate ade-
nocarcinoma with favourable-risk features defined as:
clinical stage T1-T2a according to the American Joint
Committee on Cancer (AJCC) [9], pre-treatment PSA ≤
10 ng/ml, and Gleason Score (GS) ≤ 6. Exclusion criteria
were: active inflammatory bowel disease, prior malig-
nancy (other than non-melanoma skin cancer) treated
less than 5 years prior to study enrolment, prior pelvic
RT, previous or concurrent hormone therapy, previous
therapy for prostate carcinoma, serious medical or psy-
chiatric illness precluding compliance to protocol, and
patients for whom prophylactic treatment of seminal
vesicles was deemed necessary by the radiation
oncologist.
The protocol was approved by the clinical research
and ethical committees of participating institutions.
Written informed consent was obtained from all
patients before study entry.
Staging chest x-ray, bone scan and pelvic computed
tomography (CT) scan were not compulsory, and were
left at the discretion of the treating physician.
Planning and Treatment Regimen
All patients were simulated in the supine position with a
personalized immobilization device (Vac-Lok cradle).
They were instructed to have a full bladder for the plan-
ning CT and before each treatment. No bowel prepara-
tion was used. An urethrogram was used for planning
CT, and a slice thickness of ≤ 5 mm was obtained
through the region that contained the target volumes
and organs at risk (OAR).
The clinical tumour volume (CTV) was defined as the
entire prostate. It extended inferiorly to 9-10 mm above
the tip of the urethrogram. The planning target volume
(PTV) was obtained by expanding the CTV radially with
a 1.0-1.5 cm margin on all sides, except posteriorly
where the margin was 0.5-1 cm. While these margins
are slightly larger than those used in other protocols,
they were deemed necessary to account for possible
increased intrafraction motion due to longer treatment
time (5 Gy/fraction). Moreover, only 9 fractions were
given per patient and the investigators were intent on
minimizing the risk of geographical miss. After 35 Gy (7
fractions), the margin for the PTV could be reduced to
0.5-1 cm in all directions, for example if the patient had
been shown to require only small daily shifts up to then,
and the investigator felt it safe to use current daily-ima-
ging margins of 0.5-1 cm.
Elective seminal vesicles or pelvic irradiation was not
permitted. The following OAR were outlined as solid
structures on the planningC T :r e c t u mf r o mt h ea n a l
sphincter to the rectosigmoid flexure, bladder, and
femoral heads.
Patients received 45 Gy in nine weekly fractions of five
Gy each over 9 consecutive weeks (total of 57 days)
using 3D-CRT. The dose was prescribed at the isocen-
ter, such that 100% of the PTV received ≥ 95% of the
prescribed dose and that no region in the field received
greater than 107% of the prescribed dose, as per ICRU
recommendations. An isocentric technique of 5, 6, 7 or
9 fields was used. Intensity-modulated radiation therapy
(IMRT) was not permitted. All patients were treated
with a ≥ 10 MV linear accelerator. A daily localization
procedure was mandatory using either implanted fidu-
cial gold markers or transabdominal ultrasound (B-
mode Acquisition and Targeting).
Dose constraints to OAR were based on the RTOG
P0126 protocol, and estimated using the linear-quadratic
model assuming an a/b ratio of 3 for late effects on
normal tissue (Table 1).
Study Endpoints
Primary end-points were maximal late rectal toxicity
(occurring more that 6 months after treatment) assessed
using the RTOG scale [10] (Table 2), and feasibility,
Table 1 OAR dose constraints (assuming a/b ratio of 3
for rectum and bladder)
Organ Threshold dose
(Gy)
Volume above
limit (%)
Bladder 49
45
40
15
30
50
Rectum 46
43
37
15
30
50
Right/left femoral heads 32.5 0
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pleted treatment. Secondary end-points included acute
rectal and urinary toxicity, late urinary toxicity, biochem-
ical disease free-survival (bDFS), DFS and overall survival
(OS). Biochemical failure was defined as per the Phoenix
criteria as the postradiotherapy nadir plus 2 ng/ml.
Patient Follow-up
GU and lower GI symptoms and toxicity were prospec-
tively assessed and graded by the physician at baseline
and weekly during RT. Follow-up visits were at 4 weeks
post-RT, and then every 4 months during the first year,
every 6 months during the second and third years, and
yearly thereafter. Each visit consisted of a medical his-
tory, physical examination including digital rectal exam,
and serum PSA measurement. Quality of life and sexual
function were assessed using the Expanded Prostate
Cancer Index Composite (EPIC) questionnaire. These
are not analyzed in this report.
Sample Size and Statistical Analysis
Using the baseline assumption of 8.5% ≥ grade 2 late rec-
tal toxicity, a sample size of 74 patients was required to
show with a 95% confidence interval (95% CI) that the
rate was equal or inferior to 15%. Target accrual was set
at 78 to account for a 5% loss of patients at follow-up. All
reported 95% confidence intervals are exact binomial.
Overall survival, bDFS and cumulative toxicity rates were
calculated by the actuarial method of Kaplan-Meier.
Results
Patient Characteristics and Treatment Delivery
Between March 2006 and August 2008, 81 patients were
accrued in two institutions (Centre hospitalier de l’Uni-
versité de Montréal and Centre hospitalier universitaire
de Québec). One patient withdrew consent and opted
for treatment with low dose rate brachytherapy. Patient
characteristics are shown in Table 3. No patient received
neoadjuvant, concurrent nor adjuvant hormone therapy.
As of July 2010, 80 patients had completed treatment
with a minimum follow-up of 20 months. Median fol-
low-up was 33 months (range, 20-51). All patients
received the planned dose of 45 Gy in nine weekly frac-
tions. There were no treatment interruptions. PTV cov-
erage criteria were met for all plans. Dose constraints
for the bladder were violated in four plans (55-68% of
bladder received above 40 Gy). Minor protocol devia-
tions in rectal dose constraints were found in three
cases, consisting of the deviation of a single dose-to-per-
cent volume constraint out of the three shown in Table
1. Dose constraints to femoral heads were met in all
plans. In our cohort of patients, prostatic volume did
not seem to be a factor in dosimetric violations for blad-
der or rectum. All but one patient with dosimetric viola-
tions had prostate volumes inferior to 50 cc.
Toxicity
Acute GU toxicity during treatment was common with
g r a d e0i n3 8 % ,g r a d e1i n2 9 % ,g r a d e2i n2 9 % ,a n d
grade 3 in 4%. No grade 4 acute GU toxicity occurred.
Acute GI toxicity was grade 0 in 62%, grade 1 in 27%,
Table 2 Appendix 1 - RTOG late toxicity scale
RTOG GRADE
0 I II III IV
Bladder None Slight epithelial atrophy; minor
telangiectasia (microscopic hematuria)
Moderate frequency;
generalized
telangiectasia;
intermittent
macroscopic
hematuria
Severe frequency & dysuria;
severe
telangiectasia; frequent
hematuria; reduction in
bladder capacity (< 150 cc)
Necrosis/Contracted bladder
(capacity < 100 cc); severe
hemorrhagic cystitis
Small/
Large
intestine
None Mild diarrhea; mild cramping; bowel
movement 5 times daily; slight rectal
discharge or bleeding
Moderate diarrhea
and colic; bowel
movement > 5 times
daily; excessive rectal
mucus or
intermittent bleeding
Obstruction or bleeding,
requiring surgery
Necrosis/Perforation Fistula
Table 3 Patient baseline characteristics and delivered
treatment
Median age (range) 70 years (56-77)
Clinical Stage
T1b 1 (1%)
T1c 57 (71%)
T2a 22 (28%)
Gleason Score
5 2 (2.5%)
6 79 (97.5%)
Median Initial PSA (range) 5.9 ng/ml (0.81-9.89)
Median prostate volume (range)* 41 cc (10-90)
Median Dose 45 Gy
Median Treatment Time 57 days
* as determined by TRUS or planning CT scan
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Page 3 of 8grade 2 in 11%, and no grade 3 or 4 occurred during
treatment. One month after treatment, most GU and GI
symptoms had already regressed (Table 4). Crude toxi-
city rates on treatment, at 1 month and maximal acute
toxicity are shown in Table 4.
Data for all and 52 patients were available for analysis
at 19 and 31 months, respectively, and are shown in
Table 5. Crude late grade ≥ 2 GI toxicity was 10% (95%
CI, 5 to 19) and 8% (95% CI, 2 to 19) at 19 and 31
months, respectively. Cumulative late grade ≥ 3 GI toxi-
city at 3 years is 11%. All cases of late grade 3 GI toxi-
city consisted of rectal bleeding requiring endoscopic
intervention (argon plasma coagulation), after which
most symptoms resolved and patients returned to Grade
0 or 1 toxicity. No patient underwent surgery for rectal
bleeding. Late grade 2 GU toxicity consisted mainly of
moderate frequency and dysuria. There were no cases of
late grade 3 GU toxicity. The only severe (grade 4) late
GU toxicity was a case of severe hemorrhagic cystitis,
requiring blood transfusions, four cystoscopies, disconti-
nuation of blood thinners (aspirin) and eventually radi-
cal cysto-prostatectomy for bladder necrosis.
Biochemical Response and Outcomes
At last follow-up, 2 patients had a biochemical failure by
the Phoenix definition, one with documented pelvic nodal
relapse and the other has negative digital rectal exam, pel-
vic CT scan and bone scan. Both failures were documen-
ted at 31 months follow-up. The three-year actuarial
biochemical control rate is 97%, as shown in Figure 1.
There have been no prostate cancer-related deaths at
time of manuscript preparation. Three patients died of
metastatic lung cancer of which none had a biochemical
failure at last follow-up. The three-year actuarial overall
survival rate is 94%, as shown in Figure 2.
Discussion
Although most published data from phase I/II trial do
not have sufficient follow-up to draw conclusions
regarding the efficacy of hypofractionated regimens,
early biochemical control is encouraging [11-13]. A
recent phase III randomized trial [14] comparing hypo-
fractionated (62 Gy/20 fractions/5 weeks) and conven-
tional fractionation (80 Gy/40 fractions/8 weeks) in
high-risk patients demonstrated equivalent late toxicity
and superior 3-year freedom from biochemical failure
(87% vs 79%, respectively) for the hypofractionated
arm. Many factors in this trial may confound interpre-
tation of the hypofractionation efficacy, such as the
inclusion of high risk patients, and concomitant use of
hormonal therapy for 9-months which may have had
long-term castration effect in some patients. While this
effect should in theory be balanced in the two arms, it
does reduce the power to detect a difference consider-
ing the short median follow up of 32 months. Further-
more, cross-trial comparisons of differing fractionation
schemes are limited. Hypofractionation has been the
focus of two other large randomized controlled studies
[15-17]. However, the biological doses used in both
control and hypofractionated arms are inferior to cur-
rent doses, rendering comparison of results difficult.
At least three ongoing randomized trials are studying
the effectiveness and toxicity of various hypofractio-
n a t e dR Tr e g i m e n sc o m p a r e dw i t hs t a n d a r dR T
fractionation.
Our findings show that a hypofractionated RT regi-
men consisting of 45 Gy in nine weekly fractions of five
Gy each is both feasible and well tolerated. Several char-
acteristics render the treatment regimen unique and are
worth mentioning: the fractionation scheme and total
treatment time employed, the total dose is one of the
highest BED delivered in a hypofractionated external
beam regimen and patients were treated without hormo-
nal therapy. Also, neither IMRT nor stereotactic body
RT were permitted in this study, thus allowing only the
radiobiological basis for hypofractionation to be tested,
and the toxicity outcomes were not influenced by these
newer radiation treatment delivery techniques.
Table 4 Acute urinary and rectal toxicity after prostate
EBRT
RTOG GRADE
0 I II III IV
GENITOURINARY
On-treatment 30 (38%) 23 (29%) 23 (29%) 3 (4%) -
1 month 54 (68%) 20 (25%) 5 (6%) 1 (1%) -
Maximal 28 (35%) 23 (29%) 25 (31%) 4 (5%) -
GASTROINTESTINAL
On-treatment 49 (62%) 21 (27%) 9 (11%) - -
1 month 65 (81%) 13 (16%) 2 (3%) - -
Maximal 44 (56%) 24 (30%) 11 (14%) - -
Table 5 Late urinary and rectal toxicity after prostate
EBRT
RTOG GRADE
0 I II III IV
GENITOURINARY
19 months (n = 79) 74 (94%) 1 (1%) 3 (4%) - 1 (1%)
31 months (n = 53) 47 (89%) - 5 (9%) - 1 (2%)
37 months (n = 28) 23 (82%) 1 (4%) 3 (11%) - 1 (4%)
GASTROINTESTINAL
19 months (n = 78) 61 (78%) 9 (12%) 4 (5%) 4 (5%) -
31 months (n = 52) 36 (69%) 12 (23%) 3 (6%) 1 (2%) -
37 months (n = 27) 20 (74%) 6 (22%) 1 (4%) - -
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more GI toxicity, was 8% (crude) at 31 months and the
cumulative rate at 3 years was 19%. Since median fol-
low-up is 33 months, additional toxicity is not excluded,
emphasising the importance of continued follow-up.
We found acute grade ≥ 3 GI and GU toxicity rates of
0% and 5%, respectively. Cumulative late grade ≥ 3G I
toxicity and GU toxicity were 11% and 1%. This com-
pares to results of other published studies of hypofrac-
tionated EBRT using fraction sizes ≥ 3 Gy, with acute
grade ≥ 3 GI and GU toxicity rates ranging from 0-5%
[13,18-23] and late grade ≥ 3 toxicity ranging from 0-8%
[11,13,19,20,23,24]. Table 6 compares late grade ≥ 2 rec-
tal and urinary toxicity of prospective hypofractionated
trials using large fraction sizes.
In order to compare the toxicity of this treatment with
standard fractionation RT, one can estimate that the
dose of 45 Gy/9 weekly fractions is radiobiologically
equivalent to 83.6 Gy delivered in daily 2 Gy fractions,
assuming an a/b ratio of 1.5 for prostate adenocarci-
noma. For late effects on normal tissue, this corresponds
to 72 Gy/36 fractions assuming an a/b r a t i oo f3 .T h u s ,
an increase in late normal tissue complications is not
anticipated. Comparing with standard fractionation
dose escalation trials, the Dutch trial to 78 Gy showed a
3-year cumulative incidence of late grade ≥ 3G Ia n d
GU toxicity of 4.7% and 7%, respectively [25]. Similarly,
long-term follow-up of the MDACC dose escalation
trial to 78 Gy showed grade 3 bowel toxicity of 7%, and
grade 3 GU toxicity of 4% [26].
Grade 4 toxicity is a known but infrequent complica-
tion of prostate radiation therapy [26]. Bladder and
rectal DVHs were per protocol for the patient who
developed severe cystitis. Of note, this same patient
also developed grade 3 rectal toxicity. To our knowl-
edge, late grade 4 toxicity has not been described with
hypofractionation thus far. In dose escalation trials
with standard 1.8-2 Gy fractions, late urinary and rec-
tal toxicities seem to achieve a plateau at approxi-
mately 5 years post-treatment [26], while others have
reported that late toxicity continues to develop
between 5 and 10 years after completion of therapy
[27,28]. Although at 19 months, ninety-four percent of
our patients are free of late GU toxicity (grade 0) and
no cases of grade 3 toxicity are observed, this compli-
cation is worrisome. This may be a reflection of an
inherent radiosensitivity particular to this patient, such
as a pathogenic ATM gene mutation, or may even
represent erroneous alpha/beta ratio estimates,
although this is less likely considering the mounting
b
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Figure 1 Biochemical disease-free survival with 95% confidence interval.
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prostate adenocarcinoma.
There is data to support that the a/b ratio of the
rectum is higher than the generic value of 3. Studies of
RT in endometrial, cervical and prostate cancer
[5,28-34] estimate it to be between 4 and 6, possibly as
a result of consequential late effects. Thus, for late rec-
tal injury, there is a dependency on total treatment
time, and a relative independency on dose per fraction.
In order to minimize acute rectal injury and to avoid
consequential late effects, it is important to maintain a
sufficient treatment time. For this reason, Fowler sug-
gested that total treatment time not be less than five
weeks [5], which guided the choice of schedule for this
protocol.
This hypothesis is supported by data from the Stan-
ford team who delivered 36.25 Gy in five fractions of
7.25 Gy using stereotactic body RT for localized prostate
S
u
r
v
i
v
a
l
Time (years)
Patients at risk
Figure 2 Overall survival with 95% confidence interval.
Table 6 Late rectal and urinary toxicity of prospective hypofractionation studies using ≥ 3 Gy per fraction
Author Fractionation
Schedule
Fraction Size (Gy) EQD2 if a/b 1.5
† EQD2
if a/b 3
‡
Grade ≥ 2 rectal toxicity Grade ≥ 2 urinary toxicity
Present study 45 Gy/9 5 83.6 72.0 8%/19%
§ 11%/24%
§
Martin et al (13) 60 Gy/20 3 77.1 72.0 6% (5 years) 10%
Rene et al (24) 66 Gy/22 3 84.9 79.2 25%* 32%*
Arcangeli et al (14) 62 Gy/20 3.1 81.5 75.6 17% (3 years) 14%
Coote et al (18) 57-60 Gy/19-20 3 73.3-77.1 68.4-72.0 9.5% (2 years) 8%
Madsen et al (20) 33.5 Gy/5 6.7 78.5 65.0 7.5% 20%
King et al (11) 36.25 Gy/5 7.25 90.6 74.3 15% 29%
† EQD2 if a/b 1.5 = biologically effective dose in 2 Gy fractions assuming a/b ratio of 1.5
‡EQD2 if a/b 3 = biologically effective dose in 2 Gy fractions assuming a/b ratio of 3
§Crude rate at 31 months/Cumulative three-year rate
*Worse crude rate at anytime during follow-up
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Page 6 of 8cancer. In this study, the first 21 patients were treated
on 5 consecutive days, but the treatment schedule was
subsequently modified to three fractions per week due
to the rate of rectal toxicity. Increasing the time
between fractions resulted in a significant reduction of
severe late rectal toxicity [11]. Longer treatment time, as
used in our protocol, should not have an adverse effect
on tumor control since the unusually low a/b ratio for
prostate adenocarcinoma makes these cells relatively
independent of total treatment time. This is supported
by analysis of the effect of overall treatment time on
outcome in the RTOG 75-06 and 77-06 trials [35].
One limitation of our trial may be that patients were
not treated using IMRT despite the now well documen-
ted reduction in GU and GI toxicity seen with this RT
technique [28,36,37]. We chose not to allow the use of
IMRT in our protocol as this treatment technique was
not widely available in Canada at the time the study was
initiated. Since neither IMRT nor stereotactic body RT
were allowed in this study, the acceptable toxicity rates
do not seem to result from improved radiation delivery
techniques and support the radiobiological basis for
hypofractionation. One can assume that the therapeutic
ratio of our hypofractionated regimen will likely be
enhanced with the routine use of IMRT but that needs
to be addressed in a randomized controlled trial.
Conclusions
A hypofractionated RT regimen consisting of 45 Gy in
nine once weekly fractions is both feasible and well tol-
erated, but long term follow-up is necessary to fully
assess late toxicity, tumour control and survival. In addi-
tion to the radiobiological advantages of this treatment
on tumour control, hypofractionation offers important
logistical and financial benefits, for both the patient and
the health care system. At least three large prospective
randomized trials of hypofractionation are currently
underway and results are eagerly awaited. In the mean-
time, hypofractionated RT for the curative treatment of
prostate cancer remains investigational.
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